Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.50 |
| ▸ | NR1H2 | P55055 | 6/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.41 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | STS | P08842 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL309949 | 0.92 | EPHX2 (0.50) | EPHX2NR1H2NR1H3HSD11B1SETD7 | |
| SCHEMBL309817 | 0.89 | MCL1 (0.43) | EPHX2NR1H2NR1H3HSD11B1SETD7 | |
| SCHEMBL308313 | 0.88 | EPHX2 (0.48) | EPHX2NR1H2NR1H3HSD11B1SETD7 | |
| SCHEMBL2833230 | 0.88 | EPHX2 (0.51) | EPHX2MAPTMEN1ALDH1A1TSHR | |
| SCHEMBL10042196 | 0.87 | USP2 (0.50) | EPHX2NR1H2NR1H3SETD7GPR119 | |
| SCHEMBL309691 | 0.83 | EPHX2 (0.55) | EPHX2GPR119MAPTMEN1ALDH1A1 | |
| SCHEMBL2835422 | 0.79 | EPHX2 (0.51) | EPHX2MAPTMEN1ALDH1A1TSHR | |
| SCHEMBL309655 | 0.78 | F13A1 (0.48) | EPHX2NR1H2NR1H3HSD11B1SETD7 | |
| SCHEMBL12965416 | 0.78 | F13A1 (0.48) | EPHX2NR1H2NR1H3HSD11B1SETD7 | |
| SCHEMBL8067679 | 0.77 | CTSL (0.48) | EPHX2NR1H2NR1H3HSD11B1TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536183-B2 | 3-pyridylcarbonyl-piperazinylsulfonyl derivatives | Convergence Pharmaceuticals Limited (GB) | 2013-09-17 | — | — | US | disclosed |
| US-20120302746-A1 | 3-PYRIDYLCARBONYL-PIPERAZINYLSULFONYL DERIVATIVES | BESWICK PAUL JOHN (GB) | 2012-11-29 | — | — | US | disclosed |
| EP-2300432-B1 | PIPERAZINE DERIVATIVES USED AS CAV2.2 CALCIUM CHANNEL MODULATORS | CONVERGENCE PHARMACEUTICALS (GB) | 2012-10-03 | — | — | EP | disclosed |
| US-8093249-B2 | Pyrazolo[1,5-A]pyrimidine-carbonyl-piperazine derivatives | Convergence Pharmaceuticals Limited (GB) | 2012-01-10 | — | — | US | disclosed |
| EP-2313413-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES | Convergence Pharmaceuticals Limited (GB) | 2011-04-27 | — | — | EP | disclosed |
| EP-2300432-A1 | PIPERAZINE DERIVATIVES USED AS CAV2.2 CALCIUM CHANNEL MODULATORS | Convergence Pharmaceuticals Limited (GB) | 2011-03-30 | — | — | EP | disclosed |
| WO-2010007073-A1 | PIPERAZINE DERIVATIVES USED AS CAV2.2 CALCIUM CHANNEL MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | WO | disclosed |
| US-20100016330-A1 | Novel Derivatives | Convergence Pharmaceuticals Limited (GB) | 2010-01-21 | — | — | US | disclosed |
| WO-2010007074-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016330-A1 | Novel Derivatives | CACNB2, CACNA1B, CACNA1D | EPHX2 3915/4885NR1H2 2690/4885NR1H3 3953/4885 |
| US-20120302746-A1 | 3-PYRIDYLCARBONYL-PIPERAZINYLSULFONYL DERIVATIVES | CACNB2, CACNA1C, KCNJ2 | EPHX2 4441/4885NR1H2 3689/4885NR1H3 4454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.